BIO Form 144: Notice of Proposed Sale of 760 Class A Shares

A shareholder in company symbol BIO filed a Form 144 notice to sell 760 Common Class A shares through Wells Fargo Clearing Services on the NYSE, with an aggregate market value of 228793.04.

Rhea-AI Filing Summary

A shareholder in company symbol BIO filed a Form 144 notice to sell 760 Common Class A shares through Wells Fargo Clearing Services on the NYSE, with an aggregate market value of 228793.04. The issuer reports 21906399 Common Class A shares outstanding, providing context for the relatively small size of this planned sale. The shares to be sold were acquired by donation on 09/12/2016 from Alice Schwartz as stock in kind. By signing the notice, the seller represents they are not aware of any undisclosed material adverse information about the issuer and acknowledges the requirements related to any Rule 10b5-1 trading plan.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the BIO Form 144 filing disclose?

The Form 144 filing for symbol BIO discloses a planned sale of 760 Common Class A shares on the NYSE through Wells Fargo Clearing Services, with an aggregate market value of 228793.04.

How many BIO shares are planned to be sold and what is the market value?

The shareholder plans to sell 760 Common Class A shares of issuer BIO, with an aggregate market value reported as 228793.04.

When is the approximate sale date for the BIO shares in this Form 144?

The approximate sale date disclosed for the 760 Common Class A BIO shares is 11/18/2025.

How were the BIO shares being sold in this Form 144 originally acquired?

The 760 Common Class A BIO shares were acquired on 09/12/2016 by donation from Alice Schwartz, described as stock in kind.

How many BIO Common Class A shares are outstanding according to this filing?

The filing reports that there are 21906399 Common Class A shares outstanding for the issuer associated with symbol BIO.

What representations does the seller make in the BIO Form 144 notice?

The seller represents that they do not know any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed and acknowledges representations related to any Rule 10b5-1 trading plan upon signing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/18/2025 - 01:03 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001957225
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	BIO-RAD LABORATORIES, INC.
SEC File Number	001-07928
Address of Issuer	1000 ALFRED NOBEL DRIVE HERCULES CALIFORNIA 94547
Phone	5107247000
Name of Person for Whose Account the Securities are To Be Sold	Alles Institute for Medical Research Corp
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director
Relationship to Issuer	10% Stockholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common- Class A	Wells Fargo Clearing Services 1 N. Jefferson St. Louis MO 63103	760	228793.04	21906399	11/18/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common - Class A	09/12/2016	Donation	Alice Schwartz		09/12/2016	760		Stock In Kind

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	Shares were donated to Alles Institute for Medical Research by Alice Schwartz. Alice Schwartz is associated with Alles Institute for Medical Research and is also a director and 10 percent shareholder of the issuer. Dates the shares were acquired 9/12/2016 and 12/10/2018 - Stock in kind.
Date of Notice	11/18/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Julia Schwartz
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)